Ozempic (semaglutide) Developer: Novo Nordisk Modality: Peptide PDUFA Date: January 2025 Indication/Description: Metabolic, Renal / A new indication for once-weekly subcutaneous semaglutide to treat adults with type 2 diabetes and chronic kidney disease (CKD), including delaying CKD progression and reducing the risk of kidney and cardiovascular death
FDA-Approved Weight Loss Medications Klinic Prescribes At Klinic, we exclusively offer FDA-approved, branded weight loss medications that ensure certified dosing and safety protocols
Not only did different animal models such as rats, mice, rabbits and hamsters, help in the discovery and understanding of the therapeutic pathway of GLP-1 drugs, but they also provided crucial data on drug safety, pharmacokinetics and organ-specific effects, all of which were necessary for achieving regulatory approval and the successful translation to human use
People with certain other health conditions, such as a history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy, should discuss the risks carefully with their provider
Spreading protein across meals and snacks helps maintain amino acid availability despite reduced appetite
